The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01068444 |
Recruitment Status :
Completed
First Posted : February 15, 2010
Last Update Posted : July 23, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Recent studies have demonstrated that PPARγ as well as diet control could improve glycemic control, decrease serum ALT level, decrease hepatic fat distribution, and increase intrahepatic insulin sensitivity. The purposes of this study are:
1. Primary aims:
- Comparison between Pioglitazone and placebo groups in terms of steatosis and liver function tests.
- Evaluation of clinical safety of Pioglitazone
2. Secondary aims:
- Comparison between Pioglitazone and placebo groups in terms of liver necroinflammation and fibrosis.
- The impact of Pioglitazone on the related metabolic index, including insulin resistance(HOMA-IR), newly-onset diabetes, metabolic syndrome, lipid profiles (T-Chol, HDL-C, LDL-C, TG).
- Comparison between Pioglitazone and placebo groups in terms of high-sensitive C-reactive protein changes.
3. Interventional aim: Assessment the association between magnetic resonance imaging study and intrahepatic fat distribution before and after Pioglitazone treatment.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatitis | Drug: Pioglitazone Drug: placebo | Phase 2 |
Pioglitazone belongs to thiazolidinediones and anti-diabetes drug which decreases the insulin resistance. It increases the use of glucose of peripheral tissues and decrease the production of glucose from liver and dose not influence the production of insulin. It is agonist of peroxisome proliferator-activated receptor-gamma (PPARγ) and by binding to the receptors of PPARγ in various tissues it has effects on transcription of the insulin-dependent gene. In animal model, pioglitazone has shown to influence the metabolism by the insulin-dependent mechanism.
Recent studies have demonstrated that PPARγ as well as diet control could improve glycemic control, decrease serum ALT level, decrease hepatic fat distribution, and increase intrahepatic insulin sensitivity. Meanwhile, PPARγ could also prevent the development of alcohol-induced steatohepatitis, improve hepatic necroinflammatory activity, and decrease lipid deposition. It is not yet clearly known how the effect of P-PARγ agonist among Asian peoples.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 90 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis |
Study Start Date : | April 2009 |
Actual Primary Completion Date : | July 2020 |
Actual Study Completion Date : | July 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Pioglitazone
Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment
|
Drug: Pioglitazone
Other Name: GLITOS |
Placebo Comparator: Placebo
Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment
|
Drug: placebo
placebo 30 mg/d for 6 months |
- Comparison between Pioglitazone and placebo groups in terms of steatosis and liver function tests [ Time Frame: 9 months ]
- Evaluation of clinical safety of Pioglitazone [ Time Frame: 9 months ]
- Comparison between Pioglitazone and placebo groups in terms of liver necroinflammation and fibrosis. [ Time Frame: 9 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Main inclusion criteria:
- Male and female patients with 18-70 years of age
- Liver biopsy findings consistent with the diagnosis of NASH with or without compensated cirrhosis within one year before baseline
- Compensated liver disease
- Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
- All fertile males and females must be using two forms of effective contraception during treatment during the 3 months after treatment.
- ALT level between 1.3-5 x ULN for 2 occasions during 6 months before screening.
- HbA1C ≦ 8.0 during screening
Main exclusion criteria:
- Therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) *6 months before baseline.
- History or other evidence of a medical condition associated with chronic liver disease other than NASH (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, > 20 g/day for female or > 40 g/day for male, toxin exposures)
- hepatocellular carcinoma
- History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
- Serum creatinine level >1.5 times the upper limit of normal at screening and calculated creatinine clearance as calculated by Cockcroft and Gault < 60mL/min during screening
- History of ischemic heart disease during screening
- New York Heart Association (NYHA) Functional Class 1-4 cardiac status during screening
- Albumin <3.2g/dL during screening
- Total bilirubin >1.2 x ULN during screening. Patients with history of asymptomatic indirect hyperbilirubinemia whose total bilirubin < 2 x ULN and direct bilirubin < 20% of total bilirubin could be included.
- History of prothrombin time > 15 seconds or International normalized ratio (INR) > 1.3
- Organ, stem cell, or bone marrow transplant
- History of serious concurrent medical illness that in the investigator's opinion might interfere with therapy this includes significant systemic illnesses (other than liver disease) such as chronic pancreatitis
- Active systemic autoimmune disorder
- Pregnancy (or lactation) or, in subjects capable of bearing children, inability / unwillingness to practice adequate contraception
- Females of child-bearing potential (post-puberty) unwilling or unable to have pregnancy testing at any study visit
- Therapy with a systemic antiviral agent (with the exception of prophylaxis or treatment of influenza or chronic HSV) within the past 30 days prior to screening.
- Concurrent participation in another clinical trial in which the subject is or will be exposed to another investigational or a non-investigational drug or device within 6 weeks of the screening visit
- Current therapy with insulin within 1 week prior to screening.
- Experienced use with PPARg agonist (e.g., rosiglitazone, pioglitazone) within 6 months prior to screening.
- Known hypersensitivity to any component of PPARg agonists
- A history of hepatotoxicity to TZDs and/or a history of severe edema or a medically serious fluid-related event associated with the use of TZDs
- History of metformin use within 3 months prior to screening.
- Type Ⅰ diabetes
- Seropositive of HBsAg, anti-HCV or anti-HIV during screening or 3 month prior to screening.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01068444
Taiwan | |
Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University | |
Kaohsiung City, Taiwan, 812 | |
Kaohsiung Medical University Hospital | |
Kaohsiung, Taiwan, 803 |
Principal Investigator: | Wan-Long Chuang, MD, PhD | Kaohsiung Medical University |
Responsible Party: | Wan-Long Chuang, M.D., Ph D., Kaohsiung Medical University Chung-Ho Memorial Hospital |
ClinicalTrials.gov Identifier: | NCT01068444 |
Other Study ID Numbers: |
KMUH-HB9608 |
First Posted: | February 15, 2010 Key Record Dates |
Last Update Posted: | July 23, 2020 |
Last Verified: | July 2020 |
NASH Pioglitazone Treatment |
Fatty Liver Non-alcoholic Fatty Liver Disease Liver Diseases Digestive System Diseases |
Pioglitazone Hypoglycemic Agents Physiological Effects of Drugs |